News | May 20, 2008

Treatment Within Six Weeks of AF Ablation Reduces Arrhythmias

May 21, 2008 - Antiarrhythmic drug treatment during the six weeks following atrial fibrillation (AF) ablation is well tolerated and reduces the incidence of clinically significant atrial arrhythmias and the need for cardioversion or hospitalization, according to new research released at Heart Rhythm 2008, the Heart Rhythm Society’s 29th Annual Scientific Sessions.

The 5A Study, conducted by researchers at the Hospital of the University of Pennsylvania, prospectively randomized patients with paroxysmal AF who had undergone ablation to receive antiarrhythmic drugs (AAD group) or to not receive empiric antiarrhythmic treatment (no AAD group).

“It is common for atrial arrhythmias to follow atrial fibrillation ablation early on and antiarrhythmic drugs are often prescribed during this period to reduce arrhythmia episodes, however, the benefit of this approach is unclear,” stated Jean-Francois Roux, M.D., lead author and electrophysiology fellow at the Hospital of the University of Pennsylvania in Philadelphia, PA. “Our study was designed to look at the differences in outcome between using empiric AAD treatment versus not using AAD treatment in patients with AF who had undergone ablation to determine if there are in fact benefits.”

In the AAD group, the agent was given to patients beginning the night of the procedure. In the no AAD group, only AV nodal blocking agents were prescribed. All patients wore a monitor with daily and symptomatic transmissions for four weeks after discharge and were evaluated at six weeks. Of the 110 patients enrolled, 53 were randomized to AAD and 57 to no AAD.

During the six weeks following ablation, 40 percent of patients in the no AAD group met the primary endpoint (composite of atrial arrhythmias lasting more than 24 hours, requiring hospitalization or cardioversion, or intolerance to AAD), compared to 14 percent in the AAD group. Three adverse events requiring drug termination included rash, headaches and severe fatigue.

For more information: www.hrsonline.org

Related Content

CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
FDA Approves Biosense Webster's Tag-Index Guided Ablation Software
Technology | Ablation Systems | October 09, 2018
Biosense Webster Inc. recently received approval from the U.S. Food and Drug Administration (FDA) for its Visitag...
Medtronic Cryoballoon Improves Quality of Life, Reduces Systems of Persistent Atrial Fibrillation
News | Ablation Systems | August 28, 2018
Medtronic plc announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life...
Thermedical Announces FDA IDE Approval for Clinical Study of Durablate Catheter
News | Ablation Systems | August 02, 2018
Thermedical announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device...
Boston Scientific to Acquire Cryterion Medical Inc.
News | Ablation Systems | July 13, 2018
Boston Scientific Corp. recently announced a definitive agreement to acquire Cryterion Medical Inc., a privately-held...
Treating AFib With Ablation Reduces Mortality and Stroke
News | Ablation Systems | July 05, 2018
Using catheter-based ablation instead of medications alone reduces the risks of death and stroke in patients with the...
LuxCath Showcases OmniView Light-Guided Ablation Catheter at HRS 2018
News | Ablation Systems | May 22, 2018
LuxCath LLC showcased the next generation of its proprietary OmniView light-guided catheter ablation system at the 2018...
Overlay Init